Three therapeutic areas that are essential to public health

• Immunology
  Immunology treats constitutional or acquired diseases of the immune system. Immunoglobulins - or antibodies - are indicated especially for primary immunodeficiencies, some secondary immunodeficiencies, numerous autoimmune diseases, and a number of rare diseases. 
• Intensive care
  Thousands of patients every year benefit from hospital care in emergency situations.  The therapeutic proteins proposed by LFB BIOMEDICAMENTS to the emergency services and intensive care practitioners are primarily indicated for the treatment of severe bleeding or thrombosis or for maintaining the circulating blood volume.
•  Hemostasis / Rare Diseases
  Hemostasis treats coagulation diseases and disorders such as hemophilia and other chronic or serious diseases caused by a quantitative or qualitative deficit of clotting factors. In France, LFB BIOMEDICAMENTS is the only laboratory to have proposed, alongside clotting factors VIII and IX, a pure Willebrand factor and a factor XI. In a different, but equally important area, LFB BIOMEDICAMENTS is the only laboratory in France to offer a therapeutic solution for alpha-1 antitrypsin deficiency, a rare disease.